Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

celgene europe bv - azacitidinas - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antinavikiniai vaistai - azacitidine celgene is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification,aml with >30% marrow blasts according to the who classification.

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

limedika, uab - gestodenas/etinilestradiolis - dengtos tabletės - 75 µg/30 µg - gestodene and ethinylestradiol

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - talidomidas - daugybinė mieloma - imunosupresantai - thalidomide bms in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged >/= 65 years or ineligible for high dose chemotherapy. thalidomide bms is prescribed and dispensed according to the thalidomide celgene pregnancy prevention programme (see section 4.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

celgene europe ltd. - lepirudinas - thromboembolism; thrombocytopenia - antitromboziniai vaistai - kraujo krešėjimui maţinti suaugusiems pacientams, sergantiems ii tipo heparino sukelta trombocitopenija ir tromboembolinės ligos parenterinis antitrombozinis gydymas. diagnozė turi būti patvirtinta heparino sukeltą trombocitų aktyvinimo analizės duomenys arba lygiaverčių bandymų.

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

lex ano, uab - gestodenas/etinilestradiolis - dengtos tabletės - 75 µg/30 µg - gestodene and ethinylestradiol

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

le vet beheer b.v. (nyderlandai) - tabletės - vienoje tabletėje yra: tiamazolo - 2,5 mg. - kačių hipertirozei stabilizuoti prieš tiroidektomijos operaciją. katėms, sergančioms hipertiroze, gydyti ilgą laiką.

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

le vet beheer b.v. (nyderlandai) - tabletės - vienoje tabletėje yra: tiamazolo - 5,0 mg. - kačių hipertiroizei stabilizuoti prieš tiroidektomijos operaciją. katėms, sergančioms hipertiroze, gydyti ilgą laiką.

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

biologische heilmittel heel gmbh - argentum nitricum d6/atropa bella-donna d10/ceanothus americanus d4/hydrastis canadensis d6/kalium bichromicum d8/kreosotum d12/lachesis d10/mandragora e radice siccata d10/marsdenia cundurango d6/momordica balsamina d6/mucosa coli suis d8/mucosa ductus choledochi suis d8/mucosa ilei suis d8/mucosa jejuni suis d8/mucosa nasalis suis d8/mucosa oculi suis d8/mucosa oesophagi suis d8/mucosa oris suis d8/mucosa pulmonis suis d8/mucosa pylori suis d8/mucosa recti suis d8/mucosa vesicae felleae suis d8/mucosa vesicae urinariae suis d8/oxalis acetosella d6/pankreas suis d10/phosphorus d8/psychotria ipecacuanha d8/pulsatilla pratensis d6/semecarpus anacardium d6/strychnos nux-vomica d13/sulfur d8/ventriculus suis d8/veratrum album d6 - tabletės - 1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg; 1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 m

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - immunologicals už felidae, - katės - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunologicals už felidae, - katės - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.